What Continuous Glucose Monitoring Data Can and Cannot Tell You

A continuous glucose monitor produces a beautiful, dense picture of your glucose, but the picture is only as useful as the question you bring to it, and for most people that question has a disappointing answer. The evidence is strongest, and close to settled, for one group: people who take insulin, where randomized trials show the device improves glucose control and reduces time spent dangerously low. Step outside that group and the supporting studies get thinner fast, until, for a metabolically healthy person watching post-meal bumps on a phone, there is almost nothing solid left to stand on. The sensor measures something real. Whether seeing it makes you healthier is a separate question, and the honest answer depends almost entirely on who is wearing it.

Key points#

• CGM estimates glucose in the fluid between cells, not in blood, and lags most when glucose is moving fastest.
• The firmest evidence covers people on insulin, where the device improves glucose control and cuts severe lows.
• Time in range is a genuinely useful metric, but it is still a surrogate for the complications people actually want to avoid.
• For people without diabetes, trials showing that self-tracking improves long-term health do not yet exist.
• The device is most trustworthy at the dangerous extremes and least trustworthy for small wiggles inside the normal range.

The number on the screen is a modeled estimate#

Before ranking any claim, it helps to know what the reading is. A continuous glucose monitor is a small sensor worn under the skin that samples glucose in the interstitial fluid, the liquid surrounding your cells, every few minutes and sends the result to a phone. It is not sampling blood. Sugar has to diffuse out of the capillaries before the sensor detects it, so interstitial readings trail blood glucose by several minutes, and that delay stretches when glucose is changing quickly.

Picture a tide gauge set back from the shoreline in a tidal pool. It tracks the ocean faithfully at slack tide and falls behind during a fast rise or fall. The sensor behaves the same way: its single readings are most reliable when glucose is flat and least reliable during the steep climb after a meal or the sharp drop of a coming low. That is not a manufacturing flaw; it is the physics of diffusion, and good sensors model around it. But it means any one number is a modeled guess, usually close, occasionally off, and most likely off during exactly the dramatic moments people screenshot and share. When someone waves a single alarming spike at you, the first fair question is whether that much sugar was really in the blood at all.

A ladder of claims, from firm to flimsy#

The useful way to read CGM evidence is as a ladder. The higher rungs are load-bearing; the lower ones are not.

Firmest: people who take insulin#

The most solid ground is glucose management in insulin users. In type 1 diabetes, and in type 2 treated with intensive insulin, randomized trials have shown that wearing a CGM improves measured glucose control and shortens time spent low compared with finger-stick testing alone. This matters because severe hypoglycemia is frightening and often the outcome patients dread most. A tool that lets you watch a fall approach and act before it becomes an emergency is doing real, defensible work.

Note the exact shape of the claim, though. What the trials move reliably is glucose control and time in hypoglycemia, and those are markers, not the hard endpoints of heart attack or kidney failure. Most CGM studies are neither long enough nor large enough to count complications directly. So the precise reading is that CGM improves the markers we use to predict complications and reduces the immediate danger of severe lows. That is a substantial win on its own, with no need to inflate it into something the data have not shown.

Middle: time in range#

Time in range, the share of the day glucose sits inside a target band, is the metric CGM made possible, and it is genuinely informative. A single HbA1c is a three-month average, and averages bury their extremes. Two people can share an identical HbA1c and live entirely different days: one steady inside the band, the other swinging between highs and lows that happen to cancel on paper. Time in range surfaces that difference, which is why clinicians who manage insulin lean on it (Diabetes Care 2019 international consensus).

The caution is that it remains a surrogate, and a fairly young one. It tracks roughly with HbA1c and correlates with small-vessel complications, but the trials tying a specific target directly to fewer complications are still maturing. Treat it as a working goal and a fair way to compare this month with last, not as proof that pushing the number across a line prevents some fixed amount of harm.

Flimsiest: metabolically healthy people#

The most ambitious pitch is for people without diabetes wearing a sensor to optimize wellness, and here the support nearly vanishes. The story sounds airtight: see your spikes, adjust your diet, end up healthier. But almost every link in that chain is an assumption rather than a finding. A glucose rise after a meal in someone with a normal pancreas is usually a healthy organ doing its job, not an alarm, and there is little evidence that chasing a flatter line in a metabolically healthy person changes future disease risk (systematic reviews of CGM in non-diabetic individuals and as a behaviour-change tool).

A measurement problem hides in plain sight too. When glucose bounces inside a narrow normal range, much of what the trace shows is noise, the ordinary error of the device magnified by a vertical axis zoomed in tight enough to make small ripples look like events. Treating every bump on a densely sampled line as meaningful asks the sensor for a precision it was never built to deliver at that resolution. The curiosity is not foolish and the people exploring it are not acting in bad faith; the instinct to measure is a good one. The gap is simply that the confirming trials do not yet exist. The fitting posture is interest without conviction.

Three questions for any CGM claim#

When a headline or a coach makes a claim from CGM data, three questions do most of the sorting.

Who was studied? A result proven in insulin users does not automatically carry over to someone managing diet alone, and a finding in healthy volunteers says little about established diabetes. Claims travel badly across populations.

What was measured, and for how long? A shift in a glucose metric over a few weeks is an early signal about the machinery, not proof of a complication prevented over a decade. Watch for the silent jump from "the sensor showed a spike" to "this food is harming you," with nothing in between to earn the upgrade.

Does the reading sit where the device is trustworthy? CGM excels at trends, direction, and the dangerous extremes it was designed to catch, and is far weaker at distinguishing one normal reading from another a few points away. Trust the alarms at the edges; discount the small wiggles in the middle. The device is most reliable where the stakes are highest and least reliable in precisely the range where it is most often oversold.